Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010

Chaibou, Maman Sani; Bako, H; Salisou, Laouali; Yaméogo, Tènè Marceline; Sambo, Mariama; Kim, Sung Hye; Djingarey, Mamoudou Harouna; Zuber, Patrick L. F.; Perea, William; Pezzoli, Lorenzo

doi:10.1016/j.vaccine.2012.06.006

Cited by 14 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However as GACVS (and sometimes WHO) does not have a discretionary research budget, it is dependent on persuading other stakeholders to do so. For example, when a vaccine against epidemic meningococcal meningitis A in sub-Saharan Africa was made available for mass campaigns in people aged 1–29 years, data on the safety of the vaccine during pregnancy was not available [40,41]. GACVS then made recommendations for monitoring of this safety aspect during the mass vaccination roll-out.…”

Section: Resultsmentioning

confidence: 99%

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years

Asturias

Wharton

Pless

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

In 1999, the Global Advisory Committee on Vaccine Safety (GACVS) was established by the World Health Organization (WHO) to provide independent scientific advice on issues relating to the safety of vaccines and immunization. Fifteen years onward, we conducted a multi-faceted review to evaluate the impact, reach and challenges facing GACVS, including the role GACVS plays in informing global, regional and WHO member state vaccine policy. The methods included measures of organizational structure, citation impact, themes approached, and a discussion by previous and current members to evaluate past, present and future challenges. Given the increasing range of data sources and the deployment of many new vaccines, the Committee is facing the complex task of identifying the best available evidence for recommendations on vaccine safety. To help meet the increased demand for public transparency in decision making, GACVS-structured methodology for evidence-based decisions is evolving. GACVS also promotes best practices and capacity building for timely and accurate risk assessment; risk communications; outreach to help countries maintain and, if needed, rebuild public trust in vaccines; and advocacy for bridging the major gaps in vaccine safety capacity globally.

show abstract

Section: Resultsmentioning

confidence: 99%

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years

Asturias

Wharton

Pless

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…AEFI case definitions were adapted from guidelines and those used during previous campaigns . Anyone who received the Meningococcal A Conjugate vaccine during the mass immunization campaign organized in Adamawa and North West regions of Cameroon from 3 December 2012 to 17 December 2012 was eligible.…”

Section: Methodsmentioning

confidence: 99%

“…AEFI reported in MenAfrivac TM clinical trials were described as transient and resolved withoutsequelae . The distribution of AEFI reported in MenAfrivac TM mass vaccination campaign was described during its introduction in Burkina Faso, Niger and Mali in a surveillance that lasted 42 days after immunization . Passive surveillance revealed a cumulated incidence of 9.8/100 000 people vaccinated and 3/44 serious AEFIs classified as possibly or probably related to vaccination .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

Ateudjieu

Stoll

Nguefack‐Tsague

et al. 2016

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…Abscesses following vaccination have been reported in clinical trials, number in parenthesis, from Niger 72 (5), Burkina Faso 73,74 (16, 1), Kenya 75 (17), India 76 (16) and Ethiopia 77 (10) and also in the review by Klar et al 41 . However as microbiological data were not provided in these reports it is uncertain whether these were infectious or “sterile” abscesses.…”

Section: Localized Clinical Syndromesmentioning

confidence: 99%

Sepsis, parenteral vaccination and skin disinfection

Cook

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

ASBSTRACTDisinfection should be required for all skin penetrative procedures including parenteral administration of vaccines. This review analyses medically attended infectious events following parenteral vaccination in terms of their microbiological aetiology and pathogenesis. Like ‘clean’ surgical site infections, the major pathogens responsible for these events were Staphylococcal species, implicating endogenous con-tamination as a significant source of infection. As 70% isopropyl alcohol swabbing has been shown to effectively disinfect the skin, it would be medico-legally difficult to defend a case of sepsis with the omission of skin disinfection unless the very low risk of this event was adequately explained to the patient and documented prior to vaccination. There was a significant cost-benefit for skin disinfection and cellulitis. Skin disinfection in the context of parenteral vaccination represents a new paradigm of medical practice; the use of a low cost intervention to prevent an event of very low prevalence but of significant cost.

show abstract

Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010

Cited by 14 publications

References 30 publications

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years

Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

Sepsis, parenteral vaccination and skin disinfection

Contact Info

Product

Resources

About